swara v

Safety and efficacy of allogeneic CAR-T cell for relapsed and refractory multiple myeloma

Started Mar. 1, 2024

Abstract or project description

Multiple Myeloma (MM) is a rare cancer disease that forms from a plasma cell, a type of immune cell. Currently, there aren’t many treatments to cure MM. However, chimeric antigen receptor therapy (CAR-T cell therapy) is an emerging cancer immunotherapy used to effectively treat various cancers such as leukemia, lymphoma, and multiple myeloma. Since the discovery of the new treatment, CAR-T cell therapy has undergone significant development leading to more advanced treatment for incurable cancers. This therapy uses T cells that are genetically altered in a lab which enables them in locating and destroying cancer cells more effectively. CAR-T cell therapy is given to a cancer patient if the current treatment is not effective to cure the patient. While CAR-T cell therapy is said to be effective on most cancers, some cancer patients may get the disease back after the treatment and may become resistant to it. This scenario is known as relapsed refractory multiple myeloma. Relapsed refractory multiple myeloma (RRMM) describes a stage of multiple myeloma where the cancer has returned (relapsed) and is resistant (refractory) to standard treatments. In this research paper, we compared the efficacy of the traditional CAR-T cell therapy (Autologous) and Allogeneic CAR T cell therapy on relapsed refractory multiple myeloma.